Bristol-Myers Squibb Company
HealthcareNYSE:BMY · New York Stock Exchange
+$0.23 today
Vol 3.62M · Avg 11.55M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$48.5B of revenue converted into $7.3B of net income for the selected period. Gross margin is 68.8% and net margin is 15.2%, showing how much revenue survives after costs and taxes. EPS is $3.56, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.2B -0.2% | $48.3B +7.3% | $45.0B -2.5% | $46.2B -0.5% | $46.4B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $15.6B -25.3% | $20.9B +6.2% | $19.6B -0.1% | $19.7B +0.2% | $19.6B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $32.6B +18.8% | $27.4B +8.2% | $25.4B -4.3% | $26.5B -1.0% | $26.8B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 67.6% +10.9pp | 56.8% +0.5pp | 56.3% -1.0pp | 57.4% -0.3pp | 57.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $9.6B -1.7% | $9.8B +6.2% | $9.2B -2.2% | $9.4B -1.3% | $9.5B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $7.2B -7.9% | $7.9B +2.4% | $7.7B -1.7% | $7.8B +1.6% | $7.7B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $19.9B +12.0% | $17.8B +5.3% | $16.9B -1.9% | $17.2B -0.0% | $17.2B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.9B -59.8% | $9.6B -1.6% | $9.8B -5.0% | $10.3B -3.8% | $10.7B | $374.2M | $1.2B | $631.8M |
| EBITDA | $14.5B +359.1% | $3.2B -83.6% | $19.4B +0.8% | $19.2B -4.5% | $20.1B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 30.2% +23.6pp | 6.6% -36.5pp | 43.0% +1.4pp | 41.6% -1.7pp | 43.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $12.7B +31.5% | $9.7B +14.0% | $8.5B -8.6% | $9.3B -2.8% | $9.5B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 26.3% +6.3pp | 20.0% +1.2pp | 18.8% -1.3pp | 20.1% -0.5pp | 20.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $300.0M | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.5B -22.4% | $1.9B +67.0% | $1.2B -5.4% | $1.2B -7.6% | $1.3B | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$3.4B +81.3% | -$18.0B -56265.6% | -$32.0M +97.9% | -$1.6B -8.0% | -$1.4B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $9.3B +211.3% | -$8.4B -199.3% | $8.4B +9.4% | $7.7B -4.8% | $8.1B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 19.4% +36.7pp | -17.3% -36.1pp | 18.8% +2.0pp | 16.7% -0.7pp | 17.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $2.3B +310.1% | $554.0M +38.5% | $400.0M -70.8% | $1.4B +26.2% | $1.1B | $1.3B | -$1.6B | $745.2M |
| Net Income | $7.1B +178.8% | -$8.9B -211.5% | $8.0B +26.8% | $6.3B -9.5% | $7.0B | $4.9B | $4.8B | $4.7B |
| Net Margin | 14.6% +33.2pp | -18.5% -36.4pp | 17.8% +4.1pp | 13.7% -1.4pp | 15.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +178.5% | -$4 -213.7% | $4 +30.6% | $3 -5.7% | $3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +178.2% | -$4 -214.2% | $4 +30.8% | $3 -5.4% | $3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $2.0B +0.7% | $2.0B -2.0% | $2.1B -2.9% | $2.1B -4.1% | $2.2B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $2.0B +0.7% | $2.0B -2.5% | $2.1B -3.2% | $2.1B -4.4% | $2.2B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Pfizer Inc.
NYSE:PFE
$149.18B
CVS Health Corporation
NYSE:CVS
$129.95B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.63B
GSK plc
NYSE:GSK
$106.57B
Sanofi
NASDAQ:SNY
$106.45B
McKesson Corporation
NYSE:MCK
$94.81B
Elevance Health Inc.
NYSE:ELV
$87.31B
HCA Healthcare, Inc.
NYSE:HCA
$85.73B
Cigna Corporation
NYSE:CI
$78.87B
Zoetis Inc.
NYSE:ZTS
$33.66B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BMY generate?
Bristol-Myers Squibb Company (BMY) reported $48.19B of revenue in fiscal 2025.
Is BMY profitable?
Bristol-Myers Squibb Company (BMY) reported $7.05B of net income, with a net margin of 14.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.